Scinai Immunotherapeutics Ltd. (SCNI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Scinai Immunotherapeutics Ltd. in 2026. The next earnings report is expected on August 20, 2026.
Next earnings date
20 Aug 2026
Tomorrow
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd. (SCNI) is scheduled to report earnings on August 20, 2026.
Scinai Immunotherapeutics Ltd. (SCNI) last reported earnings on November 22, 2024.
Scinai Immunotherapeutics Ltd. (SCNI) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.